ADMA Biologics Net Income
| ADMA Stock | USD 15.57 0.39 2.57% |
As of the 1st of March, ADMA Biologics shows the Coefficient Of Variation of (2,094), mean deviation of 1.94, and Risk Adjusted Performance of (0.03). ADMA Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
ADMA Biologics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.6342 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 146.9 M | 154.3 M | |
| Net Income From Continuing Ops | 227.3 M | 238.7 M | |
| Net Loss | -59.3 M | -62.3 M | |
| Net Income Per Share | 0.62 | 0.65 | |
| Net Income Per E B T | 0.80 | 0.86 |
ADMA | Net Income | Build AI portfolio with ADMA Stock |
Analyzing ADMA Biologics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing ADMA Biologics's current valuation and future prospects.
Latest ADMA Biologics' Net Income Growth Pattern
Below is the plot of the Net Income of ADMA Biologics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ADMA Biologics financial statement analysis. It represents the amount of money remaining after all of ADMA Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ADMA Biologics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ADMA Biologics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 146.93 M | 10 Years Trend |
|
Net Income |
| Timeline |
ADMA Net Income Regression Statistics
| Arithmetic Mean | (428,356) | |
| Geometric Mean | 27,686,650 | |
| Coefficient Of Variation | (19,462) | |
| Mean Deviation | 58,890,172 | |
| Median | (19,515,151) | |
| Standard Deviation | 83,367,905 | |
| Sample Variance | 6950.2T | |
| Range | 273.4M | |
| R-Value | 0.47 | |
| Mean Square Error | 5748.4T | |
| R-Squared | 0.22 | |
| Significance | 0.05 | |
| Slope | 7,824,279 | |
| Total Sum of Squares | 111203.3T |
ADMA Net Income History
Other Fundumenentals of ADMA Biologics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ADMA Biologics Net Income component correlations
ADMA Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ADMA Biologics is extremely important. It helps to project a fair market value of ADMA Stock properly, considering its historical fundamentals such as Net Income. Since ADMA Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADMA Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADMA Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.53) | Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.184 | Return On Assets |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ADMA Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ADMA Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ADMA Biologics.
| 12/01/2025 |
| 03/01/2026 |
If you would invest 0.00 in ADMA Biologics on December 1, 2025 and sell it all today you would earn a total of 0.00 from holding ADMA Biologics or generate 0.0% return on investment in ADMA Biologics over 90 days. ADMA Biologics is related to or competes with ACADIA Pharmaceuticals, Praxis Precision, Belite Bio, Ligand Pharmaceuticals, Soleno Therapeutics, Mirum Pharmaceuticals, and Dyne Therapeutics. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-... More
ADMA Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ADMA Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ADMA Biologics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 12.51 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 4.09 |
ADMA Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ADMA Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ADMA Biologics' standard deviation. In reality, there are many statistical measures that can use ADMA Biologics historical prices to predict the future ADMA Biologics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.39) | |||
| Treynor Ratio | (0.20) |
ADMA Biologics March 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 1.94 | |||
| Coefficient Of Variation | (2,094) | |||
| Standard Deviation | 2.48 | |||
| Variance | 6.17 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.39) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 12.51 | |||
| Value At Risk | (4.24) | |||
| Potential Upside | 4.09 | |||
| Skewness | 0.0766 | |||
| Kurtosis | 0.0373 |
ADMA Biologics Backtested Returns
ADMA Biologics secures Sharpe Ratio (or Efficiency) of -0.14, which signifies that the company had a -0.14 % return per unit of return volatility over the last 3 months. ADMA Biologics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm ADMA Biologics' Mean Deviation of 1.94, coefficient of variation of (2,094), and Risk Adjusted Performance of (0.03) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ADMA Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding ADMA Biologics is expected to be smaller as well. At this point, ADMA Biologics has a negative expected return of -0.33%. Please make sure to confirm ADMA Biologics' potential upside, daily balance of power, and the relationship between the maximum drawdown and kurtosis , to decide if ADMA Biologics performance from the past will be repeated in the future.
Auto-correlation | 0.64 |
Good predictability
ADMA Biologics has good predictability. Overlapping area represents the amount of predictability between ADMA Biologics time series from 1st of December 2025 to 15th of January 2026 and 15th of January 2026 to 1st of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ADMA Biologics price movement. The serial correlation of 0.64 indicates that roughly 64.0% of current ADMA Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.64 | |
| Spearman Rank Test | 0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.48 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ADMA Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ADMA Biologics reported net income of 146.93 M. This is 56.95% lower than that of the Biotechnology sector and 109.76% higher than that of the Health Care industry. The net income for all United States stocks is 74.27% higher than that of the company.
ADMA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADMA Biologics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics of similar companies.ADMA Biologics is currently under evaluation in net income category among its peers.
ADMA Biologics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADMA Biologics from analyzing ADMA Biologics' financial statements. These drivers represent accounts that assess ADMA Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADMA Biologics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 196.8M | 767.8M | 1.0B | 4.0B | 4.3B | 4.6B | |
| Enterprise Value | 248.6M | 835.7M | 1.1B | 4.0B | 4.3B | 4.6B |
ADMA Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ADMA Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ADMA Biologics' managers, analysts, and investors.Environmental | Governance | Social |
ADMA Biologics Institutional Holders
Institutional Holdings refers to the ownership stake in ADMA Biologics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ADMA Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ADMA Biologics' value.| Shares | Capital Research Global Investors | 2025-09-30 | 3.3 M | The Goldman Sachs Group Inc | 2025-09-30 | 2.9 M | Franklin Resources Inc | 2025-09-30 | 2.8 M | Caligan Partners Lp | 2025-09-30 | 2.6 M | B Group, Inc | 2025-12-31 | 2.5 M | Northern Trust Corp | 2025-09-30 | 2.4 M | Ranger Investment Management Lp | 2025-12-31 | 2.3 M | Charles Schwab Investment Management Inc | 2025-12-31 | 2.3 M | Awm Investment Company Inc | 2025-12-31 | 2.2 M | Blackrock Inc | 2025-09-30 | 35.6 M | Vanguard Group Inc | 2025-12-31 | 20.9 M |
ADMA Fundamentals
| Return On Equity | 0.36 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.29 % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 3.73 B | ||||
| Shares Outstanding | 238 M | ||||
| Shares Owned By Insiders | 3.21 % | ||||
| Shares Owned By Institutions | 94.71 % | ||||
| Number Of Shares Shorted | 21.05 M | ||||
| Price To Earning | (1.55) X | ||||
| Price To Book | 8.60 X | ||||
| Price To Sales | 7.28 X | ||||
| Revenue | 510.17 M | ||||
| Gross Profit | 292.76 M | ||||
| EBITDA | 197.86 M | ||||
| Net Income | 146.93 M | ||||
| Cash And Equivalents | 52.42 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 79.89 M | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 7.94 X | ||||
| Book Value Per Share | 2.01 X | ||||
| Cash Flow From Operations | 50.4 M | ||||
| Short Ratio | 10.26 X | ||||
| Earnings Per Share | 0.86 X | ||||
| Target Price | 25.67 | ||||
| Number Of Employees | 677 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 3.72 B | ||||
| Total Asset | 624.24 M | ||||
| Retained Earnings | (161.65 M) | ||||
| Working Capital | 275.87 M | ||||
| Current Asset | 21.29 M | ||||
| Current Liabilities | 4.22 M | ||||
| Net Asset | 624.24 M |
About ADMA Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADMA Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ADMA Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.53) | Earnings Share 0.86 | Revenue Per Share | Quarterly Revenue Growth 0.184 | Return On Assets |
ADMA Biologics's market price often diverges from its book value, the accounting figure shown on ADMA's balance sheet. Smart investors calculate ADMA Biologics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since ADMA Biologics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ADMA Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ADMA Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.